One-year trial results bolster DES (drug-eluting stent) prospects for embattled Guidant
This article was originally published in Clinica
Executive Summary
Having endured a series of setbacks in recent months, Guidant has received a welcome boost in the form of impressive clinical trial results for its drug-eluting stent (DES), Xience V.